NCT03069963View on ClinicalTrials.gov

PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

April 23, 2017

Study Completion Date

April 23, 2017

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Z0063

"Pharmaceutical form: chewable tablets~Route of administration: oral"

DRUG

Gaviscon

"Pharmaceutical form: chewable tablets~Route of administration: oral"

Trial Locations (1)

38610

Investigational Site Number 2500001, Gières

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03069963 - PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter